Brokerages Expect AC Immune SA (ACIU) to Post ($0.09) Earnings Per Share

AC Immune SA (NASDAQ:ACIU) has received a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 12 month consensus price target of $23.50 for the company and are predicting that the company will post ($0.09) EPS for the current quarter, according to Zacks. Zacks has also assigned AC Immune an industry rank of 179 out of 265 based on the ratings given to related companies.

A number of research firms have recently weighed in on ACIU. BidaskClub downgraded shares of AC Immune from a “strong-buy” rating to a “buy” rating in a research report on Friday. Zacks Investment Research downgraded shares of AC Immune from a “hold” rating to a “sell” rating in a research report on Thursday, November 16th.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN acquired a new position in AC Immune during the third quarter valued at approximately $111,000. Janney Montgomery Scott LLC acquired a new position in AC Immune during the third quarter valued at approximately $134,000. Goldman Sachs Group Inc. acquired a new position in AC Immune during the second quarter valued at approximately $127,000. Finally, Belpointe Asset Management LLC acquired a new position in AC Immune during the third quarter valued at approximately $571,000. Institutional investors own 17.12% of the company’s stock.

Shares of AC Immune (ACIU) opened at $13.14 on Friday. AC Immune has a 1 year low of $6.03 and a 1 year high of $13.75.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. sell-side analysts expect that AC Immune will post -0.57 earnings per share for the current fiscal year.

WARNING: “Brokerages Expect AC Immune SA (ACIU) to Post ($0.09) Earnings Per Share” was posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/01/21/brokerages-expect-ac-immune-sa-aciu-to-post-0-09-earnings-per-share.html.

AC Immune Company Profile

AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.

Get a free copy of the Zacks research report on AC Immune (ACIU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply